2020 Drug Metabolism Gordon Research Conference and Seminar
2020 Drug Metabolism Gordon Research Conference and Seminar
批准号:
10063328
负责人:
JAMES STEVEN LEEDER
金额:
$1.0万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-09-05 至 2022-09-04
关键词:
AcademiaAddressAnalytical ChemistryAnniversaryAtmosphereBig DataCYP2D6 geneCareer ChoiceCellsChemistryClinicalClinical PharmacologyClustered Regularly Interspaced Short Palindromic RepeatsCollaborationsComputer ModelsCytochrome P450DataDevelopmentDisciplineDoseDrug IndustryDrug KineticsEnvironmentEnzymatic BiochemistryExposure toFutureGenetic PolymorphismGrowthHearingHourIn VitroIndividualIndustryKnowledgeLearningMass Spectrum AnalysisMembrane Transport ProteinsMentorsMentorshipMetabolismMicrofluidicsModelingMolecular BiologyNatureOralOutcomePatientsPharmaceutical PreparationsPharmacodynamicsPharmacology and ToxicologyPopulationPostdoctoral FellowPrecision therapeuticsProcessPropertyRecommendationResearchResearch PersonnelRoleScienceScientific Advances and AccomplishmentsScientistSeminalTechniquesTechnologyTestingTherapeutic AgentsTimeUpdateWomanWorkabsorptioncareercareer developmentdesigndrug developmentdrug discoverydrug dispositiondrug metabolismexperiencegraduate studentin vitro activityin vivoinnovationinsightinterestmeetingsmicrobiomenovelnovel therapeuticspatient populationpostersprecision medicinereconstitutionstem cellssymposiumtherapeutic siRNA
中文摘要
项目摘要
2020年第50届药物代谢戈登研究会议(GRC)将突出已发表的、前沿的
将患者作为独特的研究对象
个人,而不是群体,作为提供精确治疗的准备步骤。
这是为了庆祝过去50年来该领域的进步,重点是
必需品
要获得的知识的组成部分是对营养物质的吸收、分布、代谢、
和消除(ADME)药物的性质。2020年大会将包括关于
药物代谢科学和大数据融合,为精准医学提供信息,并庆祝50周年
周年纪念科学会议将就会议上讨论的主题提供当代最新信息
第一次药物代谢GRC,如微生物组的药物代谢,药物代谢的机制和
体外数据对体内药物代谢的外推。主题,如膜转运蛋白、技术
如质谱学和新的治疗实体,如未知的基于siRNA的治疗剂
1971年也将被讨论。与GRC的预期一样,所有演示文稿都将包括未发布的数据,并包括会议
旨在最大限度地提高受众参与度和讨论度。我们鼓励参赛者提交海报
在由副主席简·肯尼博士组织的海报会议上展示。海报在2小时内被观看
会议的每一天都举行会议,这为互动提供了充足的时间。星期三晚上的会议
将由年轻研究人员(研究生、博士后实习生和早期职业生涯)进行口头陈述
科学家)从提交的海报摘要中挑选。这次会议是合议性和非正式的,有
有足够的机会讨论未发表的研究,建立协作联系,并开发新想法。
年轻的调查人员可以很容易地从老牌调查人员那里获得指导,以及在非正式情况下
职业建议讨论计划在一周内进行。将有一个会议,以公开讨论
在由两位职业生涯早期的女科学家领导的会议上,妇女在科学领域面临的挑战。总的来说,
这次会议将为ADME领域的研究人员提供一个机会,让他们了解尖端科学并拥有
与同事进行深入讨论,以促进协作、职业发展和学习。
英文摘要
Project Summary
The 50th Drug Metabolism Gordon Research Conference (GRC) in 2020 will highlightunpublished, cutting-edge
research patients as unique
individuals, rather than populations, as a preparatory step to delivering precision therapeutics.
that celebrates advances in the field over the past 50 years, with an emphasis on
An essential
component of the knowledge to be acquired is a clear understanding of the absorption, distribution, metabolism,
and elimination (ADME) properties of the drug. The 2020 conference will include a keynote presentation on the
integration of drug metabolism science and big data to inform precision medicine, and in celebration of the 50th
anniversary the scientific sessions will provide cutting-edge contemporary updates on topics discussed at the
first Drug Metabolism GRC, such as drug metabolism by the microbiome, mechanisms of drug metabolism and
extrapolation of in vitro data to drug metabolism in vivo. Topics, such as membrane transporters, technologies
like mass spectrometry and novel therapeutics entities, such as siRNA-based therapeutic agents unknown in
1971 will also be discussed. As expected for GRCs all presentations will include unpublished data, with sessions
designed for maximal audience participation and discussion. Attendees are encouraged to submit posters for
display at the poster sessions organized by the Vice Chair Dr. Jane Kenny. Posters are viewed during a 2-hour
session every day of the conference which provides ample time for interaction. The Wednesday evening session
will feature oral presentations by young investigators (graduate students, postdoctoral trainees and early career
scientists) selected from the submitted poster abstracts. The conference is collegial and informal in nature, with
ample opportunity to discuss unpublished research, make collaborative connections, and develop new ideas.
Young investigators have easy access to mentoring from established investigators, as well as during informal
career advice discussions planned during the week. There will be a session featuring an open discussion of
challenges faced by women in science during the meeting led by two early career women scientists. Overall,
the meeting will provide an opportunity for researchers in the ADME field to hear cutting edge science and have
in depth discussions with colleagues that will facilitate collaboration, career development and learning.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Genomic- and Ontogeny-Linked Dose Individualization and cLinical Optimization for Kids
-
批准号:9976562
-
项目类别:
-
资助金额:$68.79万
-
财政年份:2016
-
负责人:JAMES STEVEN LEEDER
-
依托单位:
Genomic- and Ontogeny-Linked Dose Individualization and cLinical Optimization for Kids
-
批准号:9229379
-
项目类别:
-
资助金额:$72.61万
-
财政年份:2016
-
负责人:JAMES STEVEN LEEDER
-
依托单位:
Pediatric Pharmacogenomics and Personalized Medicine
-
批准号:8532008
-
项目类别:
-
资助金额:$0.6万
-
财政年份:2010
-
负责人:JAMES STEVEN LEEDER
-
依托单位:
Exogenous and Endogenous Biomarkers of CYP2D6 Variability in Pediatrics
-
批准号:7760776
-
项目类别:
-
资助金额:$53.98万
-
财政年份:2010
-
负责人:JAMES STEVEN LEEDER
-
依托单位:
Pediatric Pharmacogenomics and Personalized Medicine
-
批准号:8399999
-
项目类别:
-
资助金额:$0.6万
-
财政年份:2010
-
负责人:JAMES STEVEN LEEDER
-
依托单位:
Pediatric Pharmacogenomics and Personalized Medicine
-
批准号:7916046
-
项目类别:
-
资助金额:$1.8万
-
财政年份:2010
-
负责人:JAMES STEVEN LEEDER
-
依托单位:
Exogenous and Endogenous Biomarkers of CYP2D6 Variability in Pediatrics
-
批准号:8609045
-
项目类别:
-
资助金额:$56.17万
-
财政年份:2010
-
负责人:JAMES STEVEN LEEDER
-
依托单位:
Exogenous and Endogenous Biomarkers of CYP2D6 Variability in Pediatrics
-
批准号:8249003
-
项目类别:
-
资助金额:$54.2万
-
财政年份:2010
-
负责人:JAMES STEVEN LEEDER
-
依托单位:
Pediatric Pharmacogenomics and Personalized Medicine
-
批准号:8049627
-
项目类别:
-
资助金额:$1.8万
-
财政年份:2010
-
负责人:JAMES STEVEN LEEDER
-
依托单位:
Exogenous and Endogenous Biomarkers of CYP2D6 Variability in Pediatrics
-
批准号:8437174
-
项目类别:
-
资助金额:$51.97万
-
财政年份:2010
-
负责人:JAMES STEVEN LEEDER
-
依托单位:
Exogenous and Endogenous Biomarkers of CYP2D6 Variability in Pediatrics
-
批准号:8049734
-
项目类别:
-
资助金额:$57.6万
-
财政年份:2010
-
负责人:JAMES STEVEN LEEDER
-
依托单位:
Ontogeny of Drug Bioactivation and Idiosyncratic ADRs
-
批准号:6897475
-
项目类别:
-
资助金额:$30.15万
-
财政年份:2003
-
负责人:JAMES STEVEN LEEDER
-
依托单位:
Ontogeny of Drug Bioactivation and Idiosyncratic ADRs
-
批准号:7234434
-
项目类别:
-
资助金额:$28.59万
-
财政年份:2003
-
负责人:JAMES STEVEN LEEDER
-
依托单位:
Ontogeny of Drug Bioactivation and Idiosyncratic ADRs
-
批准号:6751318
-
项目类别:
-
资助金额:$30.15万
-
财政年份:2003
-
负责人:JAMES STEVEN LEEDER
-
依托单位:
Ontogeny of Drug Bioactivation and Idiosyncratic ADRs
-
批准号:6631181
-
项目类别:
-
资助金额:$30.15万
-
财政年份:2003
-
负责人:JAMES STEVEN LEEDER
-
依托单位:
Ontogeny of Drug Bioactivation and Idiosyncratic ADRs
-
批准号:7071069
-
项目类别:
-
资助金额:$29.44万
-
财政年份:2003
-
负责人:JAMES STEVEN LEEDER
-
依托单位:
PATHOGENESIS OF ANTICONVULSANT HYPERSENSITIVITY SYNDROME
-
批准号:6386397
-
项目类别:
-
资助金额:$35.65万
-
财政年份:2000
-
负责人:JAMES STEVEN LEEDER
-
依托单位:
PATHOGENESIS OF ANTICONVULSANT HYPERSENSITIVITY SYNDROME
-
批准号:6519953
-
项目类别:
-
资助金额:$35.29万
-
财政年份:2000
-
负责人:JAMES STEVEN LEEDER
-
依托单位:
PATHOGENESIS OF ANTICONVULSANT HYPERSENSITIVITY SYNDROME
-
批准号:6636276
-
项目类别:
-
资助金额:$36.27万
-
财政年份:2000
-
负责人:JAMES STEVEN LEEDER
-
依托单位:
PATHOGENESIS OF ANTICONVULSANT HYPERSENSITIVITY SYNDROME
-
批准号:6045566
-
项目类别:
-
资助金额:$28.82万
-
财政年份:2000
-
负责人:JAMES STEVEN LEEDER
-
依托单位:
海外基金